VINS Bioproducts - Snake Venom Antiserum, Rabies Antiserum and Anti-Sera Products

VINS Bioproducts Limited (VINS) was founded by a group of professionals with proven expertise in scientific research, finance and management, with the aim of producing life saving drugs for diseases endemic in India and other less developed countries.

VINS’ state-of-the-art manufacturing facility is located 40km from Hyderabad (The Biotech Hub of India) in the serene greenery and away from polluting industries. VINS produces anti-sera products like snake venom antiserum, rabies antiserum, and other anti-sera for scorpion bites, diphtheria, tetanus, gas gangrene.

State and central government agencies and hospitals in India purchase the anti-sera products in large volumes while the retail distribution is done through its widespread distribution network which caters to medical professionals and retailers. About 30% of the sales come from exports to countries including Nepal, Pakistan, Bangladesh, Sri Lanka, Malaysia and African countries.

SNAKE VENOM ANTISERUM

The first product from VINS’ stable - the snake venom antiserum, launched in 2000 - was a runaway success. Today VINS is the major player in the Indian market for snake venom antiserum with 40% market share and has captured a sizeable chunk of the export market.

Snake venom antiserum is an equine-based immunoglobulin, enzyme treated and is available in liquid and lyophilized forms for treatment against snake bites from cobra, Russell's viper, common krait and saw-scaled viper.

RABIES ANTISERUM

Encouraged by this success, VINS went ahead to develop and produce the rabies antiserum and other anti-sera products. According to the World Health Organisation, the demand for rabies antiserum is huge and there is an acute shortage in its supply, which proves that VINS is rightly positioned in developing and producing the same.

While rabies antiserum was launched in 2002, other anti-sera products for scorpion bites, diphtheria, tetanus, gas gangrene are in the pipeline and ready for launch.

FACILITIES

The comprehensive production facilities of VINS conform to international production standards and stringent quality controls. Its facilities are accredited with ISO 9001: 200 and ISO 14001/EN ISO 14001 as well as WHO-GMP certification.

These facilities include serum processing, anti-sera blending, sterile filtration, filling, freeze drying and glassware washing, preparation and sterilisation, and cold storage facilities.

The production plant has an installed capacity to produce one million vials of biologicals and other products per annum. VINS maintains its own state-of-the-art equine farms primarily set up to obtain sera under controlled conditions. Equipped with round-the-clock support services and strictly adhering to guidelines specified by CPCSEA, highly qualified and experienced veterinarians are employed in extracting the sera from the animals.

RESEARCH AND DEVELOPMENT

VINS has a dedicated R&D team comprising of impressive scientific talent striving to develop new products in segments like haematology, cardiology, and oncology. The team's efforts also helped the company in developing cost-effective technologies without compromising on quality.

Apart from the existing facilities, VINS has planned to establish another manufacturing facility conforming to USFDA standards. While planning a joint venture with a major public sector undertaking, VINS also is planning to venture into other segments like anti-coagulants, thrombolytic enzymes (cardiology), and various classes of anti-neoplastic agents (oncology). Further, VINS has made available its manufacturing facilities to multinational clients through contract manufacturing.

CONTRACT MANUFACTURING

VINS currently undertake contract manufacturing of carboplatin, cisplatin, bleomycin, dauonorubicin, ifosfamide, epirubicin, gemcitabine, paclitaxel, docetaxel, irinotecan, mitomycin, oxaliplatin, vinorelbine tartrate, etc.